Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Plasma Derived Therapy Market Outlook

The global plasma derived therapy market size was valued at USD 24.00 billion in 2023, driven by the increasing access to medical care across the globe. The market size is anticipated to grow at a CAGR of 6.9% during the forecast period of 2024-2032 to achieve a value of USD 43.75 billion by 2032.

Plasma Derived Therapy: Introduction

Plasma-derived medicinal products are majorly used in immunology, haemostasis, and intensive care to treat rare, serious, genetic and – in many cases – life threatening diseases or conditions. These include over 80 recognized primary immunodeficiency diseases, bleeding disorders such as haemophilia and von Willebrand disease, and other genetic disorders relating to missing or non-functioning proteins typically found in blood plasma. Although they affect a relatively small percentage of the population, most are chronic conditions.

Patients generally require regular infusions or injections throughout their lives, ranging from twice a week to once a month for a primary immunodeficiency. These therapies are a lifeline, allowing patients to live a relatively normal life or significantly extending life expectancy. Plasma is a key component in the production of PDMPs. PDMPs are derived from human plasma, which is collected from donors and processed into various products. Plasma is a strategic resource to produce PDMPs, and its availability is crucial for the treatment of patients with rare diseases.

Global Plasma Derived Therapy Market Analysis

The rising investment and funding by the governments in advanced technology, along with the rising capacity expansion by the key players is primarily driving the plasma derived therapy market growth.

Plasma derived medicinal products (PDMPs) play a crucial role in prophylaxis and treatment of patients suffering from immune deficiencies, autoimmune and inflammatory diseases, bleeding disorders, and a variety of congenital deficiency disorders as well. They are used for treatment or prevention of rare clinical conditions that affects around 5 out of 10,000 people. PDMPs can be divided into four categories which are replacement or substitution therapies, immune-modulating therapies, anti-inflammatory therapies, and therapies directed to plasma protein antagonist functions. The increasing demand for PDMPs is growing gradually which is driven by increased access to medical care globally, new product launches and indications, introduction of more patient-friendly applications, and diagnostic advances that are further fuelling the global plasma derived therapy market expansion.

The development and availability of PDMPs is also expected to face some challenges due to the small size of the patient population as it would keep the costs high for the development of medicines for rare diseases.

Global Plasma Derived Therapy Market Segmentations

Market Breakup by Product

  • Immunoglobulin 
  • Coagulation Factors 
  • Albumin 
  • Others

Market Breakup by Applications

  • Hemophilia 
  • Primary immunodeficiency disease 
  • Idiopathic thrombocytopenic purpura 
  • Others

Market Breakup by Region

  • North America 
  • Europe 
  • Asia Pacific 
  • Latin America 
  • Middle East and Africa

Global Plasma Derived Therapy Market Overview

The rising geriatric population is contributing to the growth of the market. Factors such as increasing prevalence of genetic disorders, escalating use of plasma proteins in pharmaceuticals, surging autoimmune disorders, government initiatives, rising demand for albumin are also directly driving the global plasma derived therapy market development.

Factors such as increased use of immunoglobulin is also fueling the market growth. With evident improvement in diagnoses of rare diseases and earlier treatment of complex chronic diseases, the demand for PDTs has increased significantly over the last two decades. The demand for plasma derived medicinal products and therapies is increasing with, new products and indications, increased access to medical care, more patient-friendly applications, and diagnostic advances has also been adding further value to the plasma derived therapy market share. According to several international data resources it is observed that a large number of patients around the globe are not yet diagnosed with diseases that require PDMP treatment.

There are chances of these therapies becoming expensive to access in future but with rise in development of new products and expanding markets it is expected to avoid the chances of that happening which will further contribute to the demand of the plasma derived therapies in the market. There has also been an evident increase in collaborations between key players two develop new products and therapies to serve more patients which is also responsible for driving the market growth.

Plasma Derived Therapy Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • CSL Behring 
  • Takeda Pharmaceutical Company Limited 
  • BPL 
  • ADMA Biologics 
  • Biotest AG 
  • Octapharma 
  • Grifols 
  • Kamada Pharmaceuticals 
  • SK Plasma 
  • Kedrion

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product
  • Applications
  • Region
Breakup by Product
  • Immunoglobulin 
  • Coagulation Factors 
  • Albumin 
  • Others
Breakup by Applications
  • Hemophilia 
  • Primary immunodeficiency disease 
  • Idiopathic thrombocytopenic purpura 
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • CSL Behring 
  • Takeda Pharmaceutical Company Limited 
  • BPL 
  • ADMA Biologics 
  • Biotest AG 
  • Octapharma 
  • Grifols 
  • Kamada Pharmaceuticals 
  • SK Plasma 
  • Kedrion

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

Plasma derived therapy refers to treatments which are derived from human plasma. Human plasma is the clear, liquid portion of blood that remains after blood cells, platelets, and other cellular components are eliminated. It consists of water, salts, enzymes, and antibodies, among other proteins.

The market attained a value of about USD 24.00 billion in 2023, driven by the increasing geriatric population.

The market is anticipated to grow at a CAGR of 6.9% during the forecast period of 2024-2032, likely to reach a market value of USD 43.75 billion by 2032.

The increasing prevalence of rare diseases and development of new products are among the major factors driving the market growth.

Rising investments and collaborations between the key players to develop new innovative therapies to cater more patients are strongly influencing the market growth.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.

Types of products in the market include immunoglobulin, coagulation factors, albumin, among others.

They find wide applications in hemophilia, primary immunodeficiency disease, and idiopathic thrombocytopenic purpura, among others.

Key players involved in the market are CSL Behring, Takeda Pharmaceutical Company Limited, BPL, ADMA Biologics, Biotest AG, Octapharma, Grifols, Kamada Pharmaceuticals, SK Plasma, and Kedrion.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,499

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,699

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,599

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,599

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124